Dr. CATHERINE SOHN is a global biopharmaceutical executive who currently serves on the Boards of public and private life science companies. SOHN is Chairman of BioEclipse Therapeutics, a privately held, early clinical stage immuno-oncology company in the Bay Area. Additionally, she is an independent Director on the Board of Directors of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Rubius Therapeutics (NASDAQ: RUBY) and Landec Corp (NASDAQ: LNDC). She also holds the position of Adjunct Professor at the University of California, San Francisco, her alma mater.
SOHN has deep industry knowledge with thirty years of U.S. and global experience in the biopharmaceutical and consumer healthcare industries, and a reputation as a strategic thinker with the ability to drive a strong interface between research & development and marketing. She was named “Distinguished Alumnus of the Year” by the University of California, San Francisco in 2000, was named “Woman of the Year” by the Healthcare Businesswomen’s Association (HBA) in 2003, received the Licensing Executive Society’s Frank Barnes Mentoring Award (2009) and the HBA Euro-Excellence Award (2012). In 2016, SOHN was recognized as one of the PharmaVoice 100 most inspiring people in the Life Science Industry. Her areas of expertise include US and global business development, product strategy and commercialization, having led the launches of the US Vaccine Business as a start-up within a larger company and subsequently, the launch of a $1 billion CNS pharmaceutical product at SmithKline Beecham (now GSK). From 1998 to 2010, SOHN was senior vice president for worldwide business development for GlaxoSmithKline’s $6 billion Consumer Healthcare division where she was a member of the Global Executive Committee and led numerous US, global, European and Japanese transactions and integrations. In the pharmaceutical division, from 1994 to 1998, she was vice president, worldwide strategic product development at SmithKline Beecham for the cardiovascular, pulmonary and metabolic therapeutic areas for assets from Phase 1 through life cycle management. She has a strong technical background having begun her industry career in the Medical Affairs’ anti-infective group at SmithKline & French in 1982 after four years as Assistant Professor at Philadelphia College of Pharmacy.
Dr. Sohn received a Doctor of Pharmacy degree from the University of California, San Francisco, a Certificate of Professional Development from the Wharton School at the University of Pennsylvania and is a Board Leadership Fellow of the National Association of Corporate Directors (NACD).